2-氯-5-(2-乙氧基乙烯基)-嘧啶-4-胺 | 335654-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-5-(2-乙氧基乙烯基)-嘧啶-4-胺
• 英文名称: 2-chloro-5-(2-ethoxyvinyl)pyrimidin-4-amine
• 英文别名: 2-chloro-5-(2-ethoxy-vinyl)-pyrimidin-4-ylamine；2-chloro-5-(2-ethoxyvinyl)-pyrimidin-4-ylamine；2-chloro-5-(2-ethoxyethenyl)pyrimidin-4-amine
• CAS: 335654-05-2
• 化学式: C₈H₁₀ClN₃O
• 分子量: 199.64
• InChiKey: PZGLKKDFPIMFAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氯-5-(2-乙氧基乙烯基)-嘧啶-4-胺 在 palladium on activated charcoal 盐酸 、 氢气 、 氯化铵 、 pyridinium hydrobromide perbromide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 叔丁醇 为溶剂， 20.0 ℃ 、344.74 kPa 条件下， 反应 0.5h， 生成 5,7-二氢-6H-吡咯并[2,3-d]嘧啶-6-酮
  参考文献：
  名称：

  Synthesis of 2-chloro-5,7-dihydro-6 H -pyrrolo[2,3- d ]pyrimidin-6-one

  摘要：

  1,3-Dihydro-2N-indol-3-ones (oxindoles) and 1,3-dihydro-2H-pyrrolopyridin-2-ones (azaoxindoles) are useful scaffolds that have been explored for various pharmaceutical uses. Herein we report the synthesis of 2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one (5) and its derivatives, and the application of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones (diazaoxindoles) as novel scaffold to kinase research areas. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)02219-x
• 作为产物：
  描述：

  2-ethoxyvinylboronate 、 4-氨基-5-溴-2-氯嘧啶 在 四(三苯基膦)钯 、 碳酸氢钠 作用下， 以 乙二醇二甲醚 为溶剂， 生成 2-氯-5-(2-乙氧基乙烯基)-嘧啶-4-胺
  参考文献：
  名称：

  Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads

  摘要：

  Mps1, also known as TTK, is a mitotic checkpoint protein kinase that has become a promising new target of cancer research. In an effort to improve the lead-likeness of our recent Mps1 purine lead compounds, a scaffold hopping exercise has been undertaken. Structure-based design, principles of conformational restriction, and subsequent scaffold hopping has led to novel pyrrolopyrimidine and quinazoline Mps1 inhibitors. These new single-digit nanomolar leads provide the basis for developing potent, novel Mps1 inhibitors with improved drug-like properties. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.008

文献信息

• [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS<br/>[FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038417A1

  公开（公告）日：2015-03-19

  The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1
  作者：Ha-Soon Choi、Zhicheng Wang、Wendy Richmond、Xiaohui He、Kunyong Yang、Tao Jiang、Taebo Sim、Donald Karanewsky、Xiang-ju Gu、Vicki Zhou、Yi Liu、Osamu Ohmori、Jeremy Caldwell、Nathanael Gray、Yun He

  DOI：10.1016/j.bmcl.2006.01.053

  日期：2006.4

  series of 2-amino-9-aryl-7H-pyrrolo[2,3-d]pyrimidines were designed and synthesized to target focal adhesion kinase (FAK). A number of these pyrrolopyrimides exhibited low micromolar inhibitory activities against focal adhesion kinase, and their preliminary SAR was established via systematic chemical modifications. The 2-amino-9-aryl-7H-pyrrolo[2,3-d]pyrimidines represent a new class of kinase inhibitors

  设计并合成了一系列2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶，以靶向粘着斑激酶（FAK）。许多这些吡咯并嘧啶对粘着斑激酶表现出低的微摩尔抑制活性，并且它们的初步SAR是通过系统化学修饰而建立的。2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶代表了一类新的激酶抑制剂。
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS TENANT LIEU D'INHIBITEURS DE LA PROTEINE KINASE
  申请人：IRM LLC

  公开号：WO2005080393A1

  公开（公告）日：2005-09-01

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法，特别是涉及FAK、Abl、BCR-Abl、PDGF-R、c-Kit、NPM-ALK、Flt-3、JAK2和c-Met激酶异常激活的疾病或障碍。
• HETEROCYCLIC COMPOUNDS
  申请人：GAUL Christoph

  公开号：US20090203688A1

  公开（公告）日：2009-08-13

  The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  该发明涉及公式I的化合物及其盐，其中取代基如规范中定义，以及其制备方法；含有这种化合物的药物，特别用于在一个或多个蛋白酪氨酸激酶介导的疾病中使用。
• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Choi Ha-Soon

  公开号：US20070225306A1

  公开（公告）日：2007-09-27

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

  这项发明提供了一类新型化合物，包括这些化合物的药物组合物和使用这些化合物治疗或预防与异常或非调节性激酶活性相关的疾病或障碍的方法，特别是涉及FAK、Abl、BCR-Abl、PDGF-R、c-Kit、NPM-ALK、Flt-3、JAK2和c-Met激酶异常激活的疾病或障碍。